Clinical trial
Lanreotide Autogel in Patients With Acromegaly Previously Treated With…
NCT00216398 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00216398 |
|---|---|
| Title | Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR |
| Official title | A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Lanreotide (Autogel formulation) |
| Enrollment | 8 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 22, 2006 |
| Completion | Jun 22, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 16, 2019 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: